Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. 

CEO
Lars Fruergaard Jørgensen
CEOLars Fruergaard Jørgensen
Employees
63,370
Employees63,370
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1931
Founded1931
Employees
63,370
Employees63,370

NVO Key Statistics

Market cap
555.49B
Market cap555.49B
Price-Earnings ratio
45.30
Price-Earnings ratio45.30
Dividend yield
0.80%
Dividend yield0.80%
Average volume
3.21M
Average volume3.21M
High today
$124.54
High today$124.54
Low today
$119.92
Low today$119.92
Open price
$123.48
Open price$123.48
Volume
5.18M
Volume5.18M
52 Week high
$138.28
52 Week high$138.28
52 Week low
$75.56
52 Week low$75.56

NVO News

New York Times 10h
How Ozempic Is Transforming a Small Danish Town - The New York Times

As the sun sets over the harbor in Kalundborg, a small town about 60 miles west of Copenhagen, light streams through the glass walls of Shaun Gamble’s cafe and...

How Ozempic Is Transforming a Small Danish Town - The New York Times
New York Times 10h
Inside Novo Nordisk, the Company Behind Ozempic and Wegovy - The New York Times

Lars Fruergaard Jorgensen has a problem: Too many people want what he’s selling. Mr. Jorgensen is the chief executive of Novo Nordisk, the Danish drugmaker. Ev...

Inside Novo Nordisk, the Company Behind Ozempic and Wegovy - The New York Times
Yahoo Finance 16h
Weight loss drugs and the many use cases in medical treatments

Novo Nordisk's (NVO) Ozempic and Wegouvy and Eli Lilly's (LLY) Zepbound are the leading names in the latest GLP-1 weight loss drug cycle, a trend that has seen...

Weight loss drugs and the many use cases in medical treatments

Analyst ratings

66%

of 32 ratings
Buy
65.6%
Hold
25%
Sell
9.4%

More NVO News

ABC News 18h
Popular weight loss drugs in tight supply as Zepbound shortage could last through June - ABC News

Most doses of Wegovy and Zepbound have limited availability, the FDA says. Popular weight loss drugs in tight supply as Zepbound shortage could last through Ju...

Popular weight loss drugs in tight supply as Zepbound shortage could last through June - ABC News
Seeking Alpha 2d
Viking Therapeutics: An Oral Weight Loss Drug With More Data Ahead - Seeking Alpha

Xavier Lorenzo/iStock via Getty Images Viking Therapeutics, Inc. (NASDAQ:VKTX) is developing VK2735 for obesity, among other drugs in its pipeline, and has rep...

Viking Therapeutics: An Oral Weight Loss Drug With More Data Ahead - Seeking Alpha
Benzinga 2d
German Authority Gives Go Ahead To Novo Nordisk's Small Bolt On Acquisition As Danish Firm Seeks To Build Heart Drugs Pipeline

Loading... Loading... Thursday, Germany’s competition authority, Bundeskartellamt, cleared the planned acquisition of Cardior Pharmaceuticals GmbH by Danish ph...

German Authority Gives Go Ahead To Novo Nordisk's Small Bolt On Acquisition As Danish Firm Seeks To Build Heart Drugs Pipeline
Bloomberg 2d
Ozempic Babies: Doctors Want Safety Data on Obesity Shots During Pregnancy - Bloomberg

A surprising thing is happening to some women on weight-loss drugs who’ve struggled with fertility issues: They’re getting pregnant. That’s leading to questions...

Ozempic Babies: Doctors Want Safety Data on Obesity Shots During Pregnancy - Bloomberg
Yahoo Finance 2d
Metsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo - Yahoo Finance

Dive Brief: Metsera, a richly funded biotechnology startup, launched Thursday with a portfolio of weight loss drugs the company claims could eventually compete...

Metsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo - Yahoo Finance
CNBC 3d
Promise of Eli Lilly's weight-loss drug for sleep apnea adds reason to own - CNBC

Eli Lilly 's weight-loss drug Zepbound showed promise as a treatment for sleep apnea — giving investors more confidence to keep owning the world's most valuable...

Promise of Eli Lilly's weight-loss drug for sleep apnea adds reason to own - CNBC
Quartz 3d
Even more doses of Eli Lilly's Zepbound and Mounjaro are officially in a shortage, FDA says

Eli Lilly, the world’s most valuable pharmaceutical company, can’t keep up with soaring demand of its popular diabetes and weight loss drugs. Could Middle East...

Even more doses of Eli Lilly's Zepbound and Mounjaro are officially in a shortage, FDA says
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.